Living-donor liver transplantation and hepatitis C.

PubWeight™: 0.90‹?›

🔗 View Article (PMC 3564275)

Published in HPB Surg on January 21, 2013

Authors

Nobuhisa Akamatsu1, Yasuhiko Sugawara

Author Affiliations

1: Department of Hepato-Biliary-Pancreatic Surgery, Saitama Medical Center, Saitama Medical University, 1981 Tsujido-cho, Kamoda, Kawagoe, Saitama 350-8550, Japan ; Artificial Organ and Transplantation Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.

Articles cited by this

(truncated to the top 100)

Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (2009) 22.53

Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant (2006) 8.03

The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology (2002) 4.98

Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med (1996) 4.10

The role of hepatocytes and oval cells in liver regeneration and repopulation. Mech Dev (2003) 3.32

Selecting the donor liver: risk factors for poor function after orthotopic liver transplantation. Hepatology (1994) 2.73

Graft and patient survival after adult live donor liver transplantation compared to a matched cohort who received a deceased donor transplantation. Liver Transpl (2004) 2.65

Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study. J Hepatol (2008) 2.63

HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol (2000) 2.60

Successful liver transplantation from a living donor to her son. N Engl J Med (1990) 2.58

Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology (2002) 2.37

Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol (2003) 2.35

Risk factors for primary dysfunction after liver transplantation--a multivariate analysis. Transplantation (1993) 2.20

Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation. Liver Transpl (2002) 2.18

Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology (2002) 2.15

A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C. Liver Transpl (2002) 2.07

Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology (2007) 2.07

Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transpl (2003) 2.01

Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. Gastroenterology (1995) 2.00

Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology (2005) 1.97

Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology (1998) 1.95

Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation. Liver Transpl (2011) 1.92

Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection. Am J Transplant (2008) 1.86

Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl (2003) 1.86

Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol (2006) 1.86

PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl (2011) 1.85

A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. J Hepatol (2007) 1.83

Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection. J Hepatol (2010) 1.82

Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology (2005) 1.82

Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: impact of donor age and baseline cirrhosis. Liver Transpl (2009) 1.76

Histologic recurrence of chronic hepatitis C virus in patients after living donor and deceased donor liver transplantation. Liver Transpl (2004) 1.76

The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation. Liver Transpl (2008) 1.75

Patient and graft survival in hepatitis C recipients after adult living donor liver transplantation in the United States. Liver Transpl (2004) 1.74

Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology (2000) 1.72

Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant (2008) 1.70

Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study. Liver Transpl (2007) 1.68

Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transpl (2006) 1.67

Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study. Liver Transpl (2007) 1.67

A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology (1996) 1.65

Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. Hepatology (2004) 1.65

The effect of donor race on the survival of Black Americans undergoing liver transplantation for chronic hepatitis C. Liver Transpl (2009) 1.64

Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy. Liver Transpl (2008) 1.61

Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. Liver Transpl (2007) 1.61

Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology (2011) 1.59

Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl (2007) 1.58

Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial. Liver Transpl (2002) 1.58

Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation. Liver Transpl (2005) 1.58

Survival after liver transplantation using hepatitis C virus-positive donor allografts: case-controlled analysis of the UNOS database. World J Surg (2011) 1.57

Increased risk of cholestatic hepatitis C in recipients of grafts from living versus cadaveric liver donors. Liver Transpl (2003) 1.57

Influence of steroids on HCV recurrence after liver transplantation: A prospective study. J Hepatol (2007) 1.56

Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy. Liver Transpl (2009) 1.55

Retransplantation for hepatitis C: results of a U.S. multicenter retransplant study. Liver Transpl (2007) 1.54

Recipient-donor race mismatch for African American liver transplant patients with chronic hepatitis C. Liver Transpl (2012) 1.54

12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus. Liver Transpl (2006) 1.53

Epidemiology and outcome of infections in human immunodeficiency virus/hepatitis C virus-coinfected liver transplant recipients: a FIPSE/GESIDA prospective cohort study. Liver Transpl (2012) 1.53

Prolonged rewarming time during allograft implantation predisposes to recurrent hepatitis C infection after liver transplantation. Liver Transpl (2000) 1.53

Hepatic steatosis at 1 year is an additional predictor of subsequent fibrosis severity in liver transplant recipients with recurrent hepatitis C virus. Liver Transpl (2011) 1.52

Azathioprine in liver transplantation: a reevaluation of its use and a comparison with mycophenolate mofetil. Am J Transplant (2009) 1.52

Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients. Liver Transpl (2002) 1.51

Trends in post-liver transplant survival in patients with hepatitis C between 1991 and 2001 in the United States. Liver Transpl (2007) 1.51

Determination of IL28B polymorphisms in liver biopsies obtained after liver transplantation. J Hepatol (2011) 1.50

Early high peak hepatitis C viral load levels independently predict hepatitis C-related liver failure post-liver transplantation. Liver Transpl (2009) 1.50

Hepatitis C recurrence and fibrosis progression are not increased after living donor liver transplantation: a single-center study of 289 patients. Liver Transpl (2007) 1.49

Double-blind comparison of hepatitis C histological recurrence Rate in HCV+ Liver transplant recipients given basiliximab + steroids or basiliximab + placebo, in addition to cyclosporine and azathioprine. Transplantation (2004) 1.49

Natural history of recurrent hepatitis C. Liver Transpl (2002) 1.49

Living donor liver transplantation for hepatitis C-related cirrhosis: no difference in histological recurrence when compared to deceased donor liver transplantation recipients. Liver Transpl (2006) 1.48

Successful living-related partial liver transplantation to an adult patient. Lancet (1994) 1.47

Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology (2010) 1.47

Cyclosporine versus tacrolimus treated liver transplant recipients with chronic hepatitis C: outcomes analysis of the UNOS/OPTN database. Am J Transplant (2011) 1.47

Randomized controlled trial of tacrolimus versus microemulsified cyclosporin (TMC) in liver transplantation: poststudy surveillance to 3 years. Am J Transplant (2006) 1.47

Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology (2008) 1.47

Long-term, maintenance MMF monotherapy improves the fibrosis progression in liver transplant recipients with recurrent hepatitis C. Transpl Int (2011) 1.45

A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl (2002) 1.45

Longitudinal variation in hepatitis C virus (HCV) viraemia and early course of HCV infection after liver transplantation for HCV cirrhosis: the role of different immunosuppressive regimens. Gut (1999) 1.44

Pegylated interferon plus ribavirin for recurrent Hepatitis C infection after liver transplantation in naïve and non-responder patients on a stable immunosuppressive regimen. Dig Liver Dis (2005) 1.44

Accelerated hepatitis C virus kinetics but similar survival rates in recipients of liver grafts from living versus deceased donors. Hepatology (2005) 1.44

The influence of hepatitis C virus genotypes on the outcome of liver transplantation. Liver Transpl Surg (1998) 1.42

Donor age influences 10-year liver graft histology independently of hepatitis C virus infection. J Hepatol (2004) 1.41

Current status and future of liver transplantation. Semin Liver Dis (2010) 1.40

Prognostic factors for hepatitis C recurrence in patients undergoing orthotopic liver transplantation. Transpl Immunol (2006) 1.39

Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation (2001) 1.38

European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology (1999) 1.38

Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. Transplantation (2004) 1.33

Adult living donor versus deceased donor liver transplantation: a 6-year single center experience. Am J Transplant (2005) 1.31

Hepatitis C virus treatment pre- and post-liver transplantation. Liver Int (2012) 1.30

Impact of the donor risk index on the outcome of hepatitis C virus-positive liver transplant recipients. Liver Transpl (2009) 1.29

Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transpl (2008) 1.27

Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C. Am J Transplant (2006) 1.26

Liver allografts from hepatitis C positive donors can offer good outcomes in hepatitis C positive recipients: a US National Transplant Registry analysis. Transpl Int (2010) 1.25

A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology (2013) 1.21

Optimal utilization of donor grafts with extended criteria: a single-center experience in over 1000 liver transplants. Ann Surg (2006) 1.20

Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl (2003) 1.19

Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Liver Transpl Surg (1999) 1.17

Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology (1995) 1.16

Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. Liver Transpl (2007) 1.16

Post-liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria. Liver Transpl (2010) 1.15

The beneficial role of simultaneous splenectomy in living donor liver transplantation in patients with small-for-size graft. Transpl Int (2008) 1.12

Natural history of post-liver transplantation hepatitis C: A review of factors that may influence its course. Liver Transpl (2009) 1.10

Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials. Liver Transpl (2008) 1.10

Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006). J Hepatol (2006) 1.09

Articles by these authors

(truncated to the top 100)

Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol (2003) 6.14

Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology (2008) 4.61

Prognostic impact of anatomic resection for hepatocellular carcinoma. Ann Surg (2005) 4.13

One thousand fifty-six hepatectomies without mortality in 8 years. Arch Surg (2003) 3.84

Portal uptake function in veno-occlusive regions evaluated by real-time fluorescent imaging using indocyanine green. J Hepatol (2012) 2.27

Living donor liver transplantation: the Asian perspective. Transplantation (2014) 2.13

Regeneration and function of hemiliver graft: right versus left. Surgery (2006) 2.12

Impact of surgery on quality of life in patients with hepatocellular carcinoma. World J Surg (2014) 2.06

The vessel sealing system (LigaSure) in hepatic resection: a randomized controlled trial. Ann Surg (2009) 1.87

Endoscopic management of biliary complications after adult living donor liver transplantation. Am J Gastroenterol (2006) 1.78

Outcomes after living donor liver transplantation for acute liver failure in Japan: results of a nationwide survey. Liver Transpl (2012) 1.64

One orifice vein reconstruction in left liver plus caudate lobe grafts. Transplantation (2007) 1.57

Assessment of hepatic reserve for indication of hepatic resection: decision tree incorporating indocyanine green test. J Hepatobiliary Pancreat Surg (2005) 1.56

Portal vein complications after adult-to-adult living donor liver transplantation. Transpl Int (2008) 1.51

Systematic grading of morbidity after living donation for liver transplantation. Gastroenterology (2008) 1.51

Outcomes of living donor liver transplantation for hepatitis C virus-positive recipients in Japan: results of a nationwide survey. Transpl Int (2014) 1.49

Ultrasonically assisted retrohepatic dissection for a liver hanging maneuver. Ann Surg (2005) 1.46

AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. J Gastroenterol (2010) 1.44

Hepatic arterial anatomy for right liver procurement from living donors. Liver Transpl (2004) 1.44

Lower incidence of biliary carcinoma in patients with primary sclerosing cholangitis and high serum levels of immunoglobulin E. Clin Gastroenterol Hepatol (2011) 1.44

Evaluation of hepatic venous congestion: proposed indication criteria for hepatic vein reconstruction. Ann Surg (2002) 1.43

Two-stage pancreatojejunostomy in pancreaticoduodenectomy: a retrospective analysis of short-term results. Am J Surg (2008) 1.41

Bile duct preserving surgery for hepatocellular carcinoma with bile duct tumor thrombus. Ann Surg (2015) 1.41

Post-transplant lymphoproliferative disorder after adult-to-adult living donor liver transplant: case series and review of literature. Leuk Lymphoma (2010) 1.41

Sequential preoperative arterial and portal venous embolizations in patients with hepatocellular carcinoma. Arch Surg (2004) 1.37

Genome-wide association study identifies TNFSF15 and POU2AF1 as susceptibility loci for primary biliary cirrhosis in the Japanese population. Am J Hum Genet (2012) 1.32

Is there any difference in survival according to the portal tumor thrombectomy method in patients with hepatocellular carcinoma? Surgery (2009) 1.29

Virtual liver resection: computer-assisted operation planning using a three-dimensional liver representation. J Hepatobiliary Pancreat Sci (2013) 1.23

Strategies for surgical treatment of gallbladder carcinoma based on information available before resection. Arch Surg (2003) 1.21

Biliary reconstruction, its complications and management of biliary complications after adult liver transplantation: a systematic review of the incidence, risk factors and outcome. Transpl Int (2010) 1.21

Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy. Ann Surg Oncol (2009) 1.19

Modified right liver graft from a living donor to prevent congestion. Transplantation (2002) 1.16

Risk factors and management of ascites after liver resection to treat hepatocellular carcinoma. Arch Surg (2009) 1.15

Normal splenic volume in adults by computed tomography. Hepatogastroenterology (2002) 1.13

Sling suspension of the liver in donor operation: a gradual tape-repositioning technique. Transplantation (2003) 1.09

Pringle's manoeuvre in living donors. Lancet (2002) 1.08

Effects of middle hepatic vein reconstruction on right liver graft regeneration. Transplantation (2003) 1.08

Hepatocellular carcinoma: current management and future development-improved outcomes with surgical resection. Int J Hepatol (2011) 1.06

Biomarkers: evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and china. Liver Cancer (2013) 1.05

The intersegmental plane of the liver is not always flat--tricks for anatomical liver resection. Ann Surg (2010) 1.05

Visualization of subcapsular hepatic malignancy by indocyanine-green fluorescence imaging during laparoscopic hepatectomy. Surg Endosc (2014) 1.04

A worldwide survey of the current daily practice in liver surgery. Liver Cancer (2013) 1.04

The management of hepatocellular carcinoma around the world: a comparison of guidelines from 2001 to 2011. Liver Int (2012) 1.04

Cohort study of the survival benefit of resection for recurrent hepatic and/or pulmonary metastases after primary hepatectomy for colorectal metastases. Ann Surg (2010) 1.02

Duct-to-duct biliary reconstruction in adult living-donor liver transplantation. Transplantation (2004) 1.01

Gene expression profile during acute rejection in rat-to-mouse concordant cardiac xenograft by means of DNA microarray. Transpl Int (2002) 1.01

Value of prophylactic abdominal drainage in 1269 consecutive cases of elective liver resection. J Hepatobiliary Pancreat Sci (2009) 1.01

Uracil-tegafur as an adjuvant for hepatocellular carcinoma: a randomized trial. Hepatology (2006) 1.00

Tailoring the type of donor hepatectomy for adult living donor liver transplantation. Am J Transplant (2005) 1.00

Volumetric analysis of liver segments in 155 living donors. Liver Transpl (2002) 1.00

Risk factors for postoperative pancreatic fistula after pancreaticoduodenectomy: the significance of the ratio of the main pancreatic duct to the pancreas body as a predictor of leakage. J Hepatobiliary Pancreat Sci (2010) 1.00

Clinical and molecular insights into the hepatocellular carcinoma tumour marker des-γ-carboxyprothrombin. Liver Int (2010) 0.99

Right liver graft without middle hepatic vein reconstruction from a living donor. Transplantation (2002) 0.99

Giant liver hemangioma resected by trisectorectomy after efficient volume reduction by transcatheter arterial embolization: a case report. J Med Case Rep (2010) 0.99

Systematic grading of surgical complications in live liver donors according to Clavien's system. Transpl Int (2006) 0.99

Case series of 17 patients with cholangiocarcinoma among young adult workers of a printing company in Japan. J Hepatobiliary Pancreat Sci (2014) 0.99

Risk factors of post-operative recurrence and adequate surgical approach to improve long-term outcomes of hepatocellular carcinoma. HPB (Oxford) (2012) 0.99

Hepatic artery reconstruction with double-needle microsuture in living-donor liver transplantation. Liver Transpl (2006) 0.97

Pancreaticoduodenectomy after esophageal and gastric surgery preserving right gastroepiploic vessels. Arch Surg (2006) 0.97

Volume regeneration after right liver donation. Liver Transpl (2004) 0.96

Predicting operational tolerance in pediatric living-donor liver transplantation by absence of HLA antibodies. Transplantation (2013) 0.96

Estimation of standard liver volume in Japanese living liver donors. J Gastroenterol Hepatol (2006) 0.96

Living donor liver transplantation for hepatocellular carcinoma: the Japanese experience. Oncology (2011) 0.96

Surgery for multiple hepatic colorectal metastases. J Hepatobiliary Pancreat Surg (2004) 0.95

Effectiveness of hepatic resection for early-stage hepatocellular carcinoma in cirrhotic patients: subgroup analysis according to Milan criteria. Jpn J Clin Oncol (2007) 0.95

Identification of veno-occlusive regions in a right liver graft after reconstruction of vein segments 5 and 8: application of indocyanine green fluorescence imaging. Liver Transpl (2013) 0.94

Bloodstream infection after living donor liver transplantation. Scand J Infect Dis (2008) 0.94

The management of hepatocellular carcinoma in Asia: a guideline combining quantitative and qualitative evaluation. Biosci Trends (2010) 0.94

Application of fluorescent cholangiography to single-incision laparoscopic cholecystectomy. Surg Endosc (2011) 0.94

Effect of c-Met inhibitor SU11274 on hepatocellular carcinoma cell growth. Biosci Trends (2011) 0.94

Progress in surgical treatment of hepatocellular carcinoma. Oncology (2002) 0.93

Low hepatitis C viral load predicts better long-term outcomes in patients undergoing resection of hepatocellular carcinoma irrespective of serologic eradication of hepatitis C virus. J Clin Oncol (2012) 0.93

Surgical strategy for bile duct cancer: Advances and current limitations. World J Clin Oncol (2011) 0.92

Hepatobiliary surgery guided by a novel fluorescent imaging technique for visualizing hepatic arteries, bile ducts, and liver cancers on color images. J Am Coll Surg (2011) 0.92

Indocyanine green fluorescent imaging for detecting extrahepatic metastasis of hepatocellular carcinoma. J Gastroenterol (2012) 0.91

Clinical utility of simultaneous measurement of alpha-fetoprotein and des-γ-carboxy prothrombin for diagnosis of patients with hepatocellular carcinoma in China: A multi-center case-controlled study of 1,153 subjects. Biosci Trends (2014) 0.91

Perspectives on human clinical trials of therapies using iPS cells in Japan: reaching the forefront of stem-cell therapies. Biosci Trends (2013) 0.91

Clinical significance of subcellular localization of KL-6 mucin in primary colorectal adenocarcinoma and metastatic tissues. World J Gastroenterol (2006) 0.91

Hepatic resection with reconstruction of the inferior vena cava or hepatic venous confluence for metastatic liver tumor from colorectal cancer. J Am Coll Surg (2004) 0.91

Caval invasion by liver tumor is limited. J Am Coll Surg (2008) 0.90

Recurrence of primary sclerosing cholangitis after living donor liver transplantation. Liver Int (2007) 0.90

Evaluation methods for pretransplant oncologic markers and their prognostic impacts in patient undergoing living donor liver transplantation for hepatocellular carcinoma. Transpl Int (2014) 0.90

Diagnostic accuracy of multidetector-row computed tomography for hilar cholangiocarcinoma. J Gastroenterol Hepatol (2010) 0.89

Impaired volume regeneration of split livers with partial venous disruption: a latent problem in partial liver transplantation. Transplantation (2002) 0.89

Comparison of the therapeutic outcomes between surgical resection and percutaneous ablation for small hepatocellular carcinoma. Ann Surg Oncol (2014) 0.89

Photodynamic therapy for human hepatoma-cell-line tumors utilizing biliary excretion properties of indocyanine green. J Gastroenterol (2013) 0.89

Step-by-step vascular naming algorithms for a precise understanding of major anomalies in the liver. Hepatogastroenterology (2012) 0.88

Role of splenectomy in living-donor liver transplantation for adults. Hepatogastroenterology (2002) 0.88

Diagnostic accuracy of α-fetoprotein and des-γ-carboxy prothrombin in screening for hepatocellular carcinoma in liver transplant candidates. Hepatol Res (2011) 0.88

Further study of anti-ICOS immunotherapy for rat cardiac allograft rejection. Surg Today (2008) 0.88

Hidden symmetry in asymmetric morphology: significance of Hjortsjo's anatomical model in liver surgery. Hepatogastroenterology (2012) 0.87

Gastrointestinal bleeding after living-related liver transplantation. Dig Dis Sci (2002) 0.87

Noninvasive estimation of hepatic steatosis in living liver donors: usefulness of visceral fat area measurement. Transplantation (2009) 0.87

Fulminant hepatic failure associated with triazolam. Dig Dis Sci (2002) 0.87

Surgical technique: new advances for expanding indications and increasing safety in liver resection for HCC: the Eastern perspective. J Hepatobiliary Pancreat Sci (2009) 0.87

Clinicopathology of sialomucin: MUC1, particularly KL-6 mucin, in gastrointestinal, hepatic and pancreatic cancers. Biosci Trends (2009) 0.86

Above 5 cm, size does not matter anymore in patients with hepatocellular carcinoma. World J Surg (2014) 0.86

Acquisition of methicillin-resistant Staphylococcus aureus after living donor liver transplantation: a retrospective cohort study. BMC Infect Dis (2008) 0.86

Liver transplantation using hepatitis B core antibody-positive grafts: review and university of Tokyo experience. Dig Dis Sci (2007) 0.86

Morphological regeneration and hepatic functional mass after right hemihepatectomy. Dig Surg (2006) 0.86